Drug tested in youngest ever type 1 diabetes patients

NCT ID NCT05757713

Summary

This study is testing the safety and how the body processes teplizumab in very young children (under 8 years old) who have early signs of type 1 diabetes but haven't developed full symptoms yet. About 20 children will receive the drug through daily IV infusions for 14 days, and researchers will monitor them for side effects and track how the drug moves through their bodies. The goal is to understand if this treatment is safe for young children who are at high risk of developing type 1 diabetes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barbara Davis Center for Diabetes Site Number : 102

    Aurora, Colorado, 80045, United States

  • Centricity Research Site Number : 104

    Columbus, Georgia, 31904, United States

  • Children's Hospital of Philadelphia Site Number : 108

    Philadelphia, Pennsylvania, 19104, United States

  • Indianapolis University Health Riley Hospital for Children Site Number : 110

    Indianapolis, Indiana, 46202, United States

  • MulitCare Institute for Research & Innovation Site Number : 103

    Tacoma, Washington, 98405, United States

  • Sanford Diabetes and Thyroid Clinic Site Number : 106

    Sioux Falls, South Dakota, 57105, United States

  • UBMD Pediactrics Site Number : 105

    Buffalo, New York, 14203, United States

  • UCSF Medical Center Site Number : 107

    San Francisco, California, 94143, United States

  • Vanderbilt Univerity Medical Center Site Number : 109

    Nashville, Tennessee, 37232, United States

  • Yale University School of Medicine Site Number : 101

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.